Urology Times Newsletter

FOCUS ON: BLADDER CANCER

Sequential gemcitabine/docetaxel promising for recurrent NMIBC

"In this era of BCG shortage, we may be forced to develop new standards and alternative strategies for bladder preservation," writes Badar M. Mian, MD.

Read his column

Long-term QoL data support adding chemo to RT for localized MIBC

“Our study showed that at least with the regimen used in our trial, patients can have chemotherapy in addition to radiotherapy without any fear that it will impair their quality of life,” says researcher Robert A. Huddart, MD, PhD.

Learn more

Are you sure it’s really a Blue Light Cystoscopy?

Marketplace confusion is running high. Be sure you know the facts about the Blue Light Cystoscopy that the 2016 AUA/SUO Guideline says should be used (Moderate Recommendation, Grade B).

Read the Guideline statement and more.

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

Progress for mCRPC with AR-targeted therapies

In this Urology Times^® supplement, a roundtable of expert urologists and oncologists addresses common questions about patient evaluation and management of castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC.

Read it now.